ELMSFORD, N.Y.--(

纽约州埃尔姆斯福德--(

BUSINESS WIRE

商业热线

)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced the completion of the acquisition of ENvue Medical Holdings Corp. (“ENvue”) (the “Acquisition”), a privately-held, innovative leader in enteral feeding solutions.

)--NanoVibronix，Inc.（纳斯达克代码：NAOV）（以下简称“公司”）是一家专门从事非侵入性治疗设备的医疗技术公司，今天宣布完成对ENvue medical Holdings Corp.（以下简称“ENvue”）的收购，ENvue medical Holdings Corp.（以下简称“收购”），这是一家私营的创新型肠内喂养解决方案领导者。

This strategic transaction will combine the strengths of both companies, creating a platform for growth and expanded market reach in the medical device sector. The Company believes that the Acquisition will strengthen the combined company’s market position in enteral feeding technology and therapeutic medical devices, as ENvue’s proprietary technology aligns with the Company’s commitment to patient safety and advanced medical solutions and the combined company is expected to benefit from a broader commercial platform, enhanced distribution and operational efficiencies..

这项战略性交易将结合两家公司的优势，为医疗器械行业的增长和扩大市场范围创造一个平台。该公司认为，此次收购将加强合并公司在肠内喂养技术和治疗性医疗器械方面的市场地位，因为ENvue的专有技术符合该公司对患者安全和先进医疗解决方案的承诺，并且合并公司预计将受益于更广泛的商业平台，提高分销和运营效率。。

Brian Murphy, CEO of NanoVibronix, Inc., stated:

NanoVibronix，Inc.首席执行官布莱恩·墨菲（BrianMurphy）表示：

'This transaction represents a transformational opportunity for NanoVibronix and our shareholders. ENvue Medical has developed an innovative solution that directly addresses critical patient safety challenges in enteral feeding, and we are excited to integrate their technology into our portfolio. Together, we are positioned to accelerate growth, improve patient outcomes and create long-term value for our shareholders.'.

“这项交易为NanoVibronix和我们的股东提供了一个转型机会。ENvue Medical开发了一种创新解决方案，可直接解决肠内喂养中关键的患者安全挑战，我们很高兴将他们的技术整合到我们的产品组合中。我们共同致力于加速增长，改善患者的治疗效果，并为股东创造长期价值。”。

Dr. Doron Besser, CEO of ENvue Medical Holdings, Corp., added:

ENvue Medical Holdings，Corp.首席执行官Doron Besser博士补充道：

'Joining forces with NanoVibronix marks the beginning of an exciting new chapter for ENvue Medical. Our combined expertise, market presence and commitment to innovation will allow us to reach more hospitals and healthcare providers with life-saving solutions. We look forward to bringing our cutting-edge enteral feeding technology to a broader audience and making a meaningful impact in patient care.'.

“与NanoVibronix的联手标志着ENvue Medical激动人心的新篇章的开始。我们的专业技能、市场占有率和创新承诺相结合，将使我们能够为更多的医院和医疗保健提供者提供救生解决方案。我们期待着将我们最先进的肠内喂养技术带给更广泛的受众，并在患者护理方面产生有意义的影响。”。

About the Acquisition and the Private Placement

关于收购和私募

The Acquisition of ENvue was structured as a stock-for-stock transaction pursuant to which all of ENvue’s outstanding equity interests were exchanged based on a fixed exchange ratio for consideration as a combination of 1,734,995 shares of the Company common stock, which such number of shares represented no more than 19.9% of the outstanding shares of Company common stock as of immediately before the effective time of the Acquisition, and 57,720 shares of Series X Non-Voting Convertible Preferred Stock (the “Series X Preferred Stock”) (or 57,720,000 shares of common stock on an as-converted-to-common basis).

ENvue的收购是一项以股换股的交易，根据该交易，ENvue的所有已发行股权均按照固定的交换比率进行交换，以作为公司普通股1734995股的组合，截至收购生效之前，该数量的股份不超过公司普通股已发行股份的19.9%，以及57720股X系列无投票权可转换优先股（“X系列优先股”）（或57720000股转换为普通股）。

Subject to Company stockholder approval, each share of Series X Preferred Stock will automatically convert into 1,000 shares of common stock, subject to certain beneficial ownership limitations set by each holder..

经公司股东批准，X系列优先股的每股将自动转换为1000股普通股，但须符合每位股东设定的某些实益所有权限制。。

After giving effect to Acquisition and pursuant to the terms and conditions of the merger agreement governing the Acquisition, (i) the holders of the outstanding equity of ENvue immediately prior to the effective time of the first merger (“First Effective Time”) own 19.9% of the common stock of the Company and 85.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective Time, which following stockholder approval will allow the Series X Preferred Stock to convert to common stock of the Company, which may result in the holders of ENvue holding 85% of the common stock of the Company, and (ii) the holders of our outstanding equity immediately prior to the First Effective Time holding 80.1% of the common stock of the Company and 15.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective Time, which following stockholder approval will allow the Series X Preferred Stock to convert to common stock of the Company which may result in our holders holding 15% of common stock of the Company..

收购生效后，根据合并协议中有关收购的条款和条件，（i）在第一次合并生效之前（“第一次生效时间”）ENvue流通股的持有人拥有公司19.9%的普通股和85.0%的流通股（假设X系列优先股以1000:1的比例转换），在第一次生效之后，股东批准后将允许X系列优先股转换为公司普通股，这可能导致ENvue持有人持有公司85%的普通股，以及（ii）在第一次生效之前，我们流通股的持有人第一生效时间后，立即持有公司80.1%的普通股和15.0%的已发行股本（假设X系列优先股以1000:1的比例转换），股东批准后，X系列优先股将转换为公司普通股，这可能导致我们的股东持有公司15%的普通股。。

Following the consummation of the Acquisition, a successor-in-interest of ENvue will become a wholly-owned subsidiary of the Company. The Acquisition was approved by the Board of Directors of Company and the Board of Directors and stockholders of ENvue and was consummated on February 14, 2025.

收购完成后，ENvue的继承人将成为公司的全资子公司。本次收购得到了公司董事会和ENvue董事会及股东的批准，并于2025年2月14日完成。

Concurrently with the completion of the Acquisition, the Company consummated a private placement investment with an institutional investor, pursuant to which the Company sold in a private placement a senior convertible debenture (the “Debenture”) having an aggregate principal amount of $500,000 (the “Debenture Transaction”).

在收购完成的同时，公司完成了与机构投资者的私募投资，根据该投资，公司在私募中出售了本金总额为50万美元的高级可转换债券（“债券交易”）。

Following the receipt of stockholder approval, the Debenture is convertible, in whole or in part, into shares of the Company’s common stock, at the option of the holder, at the initial conversion price of $0.4446, which is subject to customary anti-dilution adjustments, and which such conversion price shall not be lower than the floor price of $0.08892 (“Debenture Shares”)..

在收到股东批准后，债券可以全部或部分转换为公司普通股的股票，由股东选择，初始转换价格为0.4446美元，这需要按照惯例进行反稀释调整，并且该转换价格不得低于0.08892美元的底价（“债券股”）。。

Palladium Capital Group, LLC served as the exclusive advisor on the transaction. Haynes and Boone, LLP acted as legal advisor to ENvue. Pierson Ferdinand, LLP acted as legal advisor to the Company.

钯资本集团有限责任公司担任该交易的独家顾问。Haynes和Boone，LLP担任ENvue的法律顾问。Pierson Ferdinand，LLP担任该公司的法律顾问。

The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws.

私募中出售的证券尚未根据1933年《证券法》（修订版）（“证券法”）或适用的州证券法进行登记，除非根据有效的登记声明或适用的《证券法》和适用的州或其他司法管辖区证券法的登记要求豁免，否则不得在美国发售或出售。

Pursuant to the terms of the merger agreement for the Acquisition and the registration right agreement governing the private placement, the Company has agreed to file a registration statement (the “Resale Registration Statement”) with the Securities and Exchange Commission (the “SEC”) registering the resale of Debenture Shares, the shares of Company common stock issued in the Acquisition, and the share of common stock issuable upon conversion of the Series X Preferred Stock issued in the Acquisition..

根据收购合并协议和私募登记权协议的条款，公司同意向证券交易委员会（“SEC”）提交登记声明（“转售登记声明”），登记债券股份的转售、收购中发行的公司普通股股份以及收购中发行的X系列优先股转换后可发行的普通股股份。。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities of the Company in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或招揽购买要约，也不构成本公司在任何州或其他司法管辖区的证券销售，在任何州或其他司法管辖区的证券法律规定的登记或资格之前，该等要约、招揽或销售将是非法的。。

Management and Organization

管理和组织

NanoVibronix and ENvue will continue to be led by its current management team, with the addition of Doron Besser of ENvue and Professor Zeev Rotstein as directors, and resignation of Harold Jacob, M.D., Maria Schroeder and Michael Ferguson from the board of directors of the Company. Following the Acquisition, the Company board of directors will be comprised of Brian Murphy, Christopher Fashek, Martin Goldstein, Thomas R.

NanoVibronix和ENvue将继续由目前的管理团队领导，ENvue的Doron Besser和Zeev Rotstein教授将担任董事，哈罗德·雅各布（Harold Jacob），医学博士（Maria Schroeder）和迈克尔·弗格森（Michael Ferguson）将辞去公司董事会职务。收购完成后，公司董事会将由布莱恩·墨菲、克里斯托弗·法舍克、马丁·戈尔茨坦、托马斯·R。

Mika, Aurora Cassirer, Doron Besser, M.D., and Professor Zeev Rotstein, M.D..

Mika、Aurora Cassirer、医学博士Doron Besser和医学博士Zeev Rotstein教授。。

About NanoVibronix, Inc.

关于NanoVibronix，Inc。

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief.

NanoVibronix，Inc.（纳斯达克股票代码：NAOV）是一家医疗器械公司，总部位于德克萨斯州泰勒，在以色列奈瑟进行研发，专注于利用其专利的低强度声表面波（SAW）技术开发医疗器械。该专有技术允许产生低频超声波，可用于各种医疗应用，包括破坏生物膜和细菌定植，以及缓解疼痛。

The devices can be administered at home without the continuous assistance of medical professionals. The Company’s primary products include PainShield® and UroShield®, which are portable devices suitable for administration at home or in any care setting. Additional information about NanoVibronix is available at: .

这些设备可以在家中管理，而无需医疗专业人员的持续帮助。该公司的主要产品包括PainShield®和UroShield®，它们是适合在家中或任何护理环境中使用的便携式设备。有关NanoVibronix的其他信息，请访问：。

www.nanovibronix.com

纳米振动棒

.

.

About ENvue Medical Holdings Corp.

关于ENvue Medical Holdings Corp。

ENvue Medical Holdings Corp is a leader in electromagnetic navigation technology, providing real-time guidance for enteral feeding tube placement across critical care, step-down units, and general medical-surgical floors in hospitals. The FDA 510(k)-cleared ENvue System and feeding tube are designed to support precise and efficient placement, enabling clinicians to navigate feeding tubes with confidence, while reducing the risk of misplacement and complication.

ENvue Medical Holdings Corp是电磁导航技术的领导者，为医院重症监护室、降压室和普通医疗手术室的肠内营养管放置提供实时指导。FDA 510（k）许可的ENvue系统和饲管旨在支持精确有效的放置，使临床医生能够自信地导航饲管，同时降低错位和并发症的风险。

Already in use at numerous hospitals across the United States, ENvue improves workflow efficiency and enhances patient care by offering a reliable alternative to traditional blind placement methods..

ENvue已经在美国的许多医院使用，它通过提供传统盲人安置方法的可靠替代方案，提高了工作流程效率并增强了患者护理。。

Built on Enhanced Navigation (EN), ENvue isa platform technology system with the potential to expand beyond enteral feeding into areas such as vascular access, positioning the company for long-term growth in multiple medical applications.

ENvue isa平台技术系统建立在增强导航（EN）的基础上，有可能超越肠内喂养扩展到血管通路等领域，为公司在多种医疗应用中的长期增长奠定基础。

With a strong foundation in clinical innovation and adoption in leading healthcare institutions, ENvue Medical is advancing the future of guided medical navigation. Additional information about the ENvue System and feeding tubes is available at:

凭借强大的临床创新基础和领先医疗机构的采用，ENvue Medical正在推动引导医疗导航的未来。有关ENvue系统和进料管的其他信息，请访问：

www.envuemed.com

www.envuemed.com

.

.

Forward-looking Statements

前瞻性声明

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements include, but are not limited to: future expectations, plans and prospects for the Company following the consummation of the acquisition and stockholder approval of the conversion of the Series X Preferred Stock.

本新闻稿包含“前瞻性声明”。此类声明之前可能会有“打算”、“可能”、“将会”、“计划”、“期望”、“预期”、“项目”、“预测”、“估计”、“目标”、“相信”、“希望”、“潜在”或类似的词语。这些前瞻性陈述包括但不限于：在完成收购和股东批准X系列优先股转换后，公司的未来预期、计划和前景。

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

前瞻性陈述不是对未来业绩的保证，是基于某些假设，并受到各种已知和未知的风险和不确定性的影响，其中许多风险和不确定性超出了公司的控制范围，无法预测或量化；因此，实际结果可能与此类前瞻性声明中明示或暗示的结果存在重大差异。

Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S.

此类风险和不确定性包括但不限于与以下相关的风险和不确定性：（i）市场对我们现有和新产品的接受程度或关键市场的长期产品延迟；（ii）阴性或不可靠的临床试验结果；（iii）无法获得销售我们产品的监管批准；（iv）大型跨国公司在医疗器械行业的激烈竞争；（v） 产品责任索赔；（vi）产品故障；（vii）我们有限的制造能力和对分包商援助的依赖；；（ix）我们成功获得和维护产品知识产权保护的能力；（x） 影响美国医疗体系的立法或监管改革。

or in foreign jurisdictions; (xi) our relian.

或在外国司法管辖区；（xi）我们的信赖。

http://www.sec.gov

http://www.sec.gov

. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

。